We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
$50 for your first 3 months Get the print edition and steer from crisis to recovery
Add this topic to your myFT Digest for news straight to your inbox
Approach seeks to cut years off traditional licensing process for treatments
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
Executive vice-president Robert Davis will take helm at US drugmaker
After lacklustre results, company says it will shift focus to potential drugs to treat the disease
US pharma group says Britain is ‘world leader’ in developing science
Wayne Holman and his wife Wendy are betting they can change the course of the pandemic
Pharma group’s publicity-shy chief has made a remarkable intervention over George Floyd’s killing
Pill that aims to force virus to mutate to self-destruction set for extensive clinical trials in US and UK
Ken Frazier calls 12 to 18-month targets ‘very aggressive’ as he announces biotech acquisition
On paper, the spin-off looks promising, but there is some pause for thought
New company with $6.5bn in revenue will include women’s health unit and legacy brands
Drugs group unveils tighter strategic vision as Merck also acquires oncology biotech
Pharmaceutical company also reports boost from vaccine targeting human papillomarivus
Sales rose 12 per cent driven by a rise in revenue from tumour treatment Keytruda
Dovato shown to be as effective as Gilead’s traditional combination treatment
Amgen, Merck and Eli Lilly say Trump administration’s move infringes on free speech
Hopeful results for blockbuster immunotherapy drug
Group that is developing a renal cancer treatment had been planning a New York listing
Pfizer, Eli Lilly and Merck raise earnings forecasts for 2019
US pharmaceutical company reported better than expected sales and earnings
Merck collaboration for new generation of pills could be worth as much as $340m
Rapid medical innovation is prompting drug company mergers and making treatment costly
Virgin looks to expand in the US, Theresa May is expected to ask MPs for more time t…
The immunotherapy used with Pfizer’s Inlyta halves the risk of dying from condition
International Edition
